MJDF Pharmacology & Pain Control 3

Question 1

What class of drug is tramadol and what are its relevant side effects for dental patients?

Accepted Answer

Atypical opioid (μ-receptor agonist + SNRI); causes nausea, dizziness, reduces seizure threshold

Answer

Tramadol acts as a weak μ-opioid receptor agonist and inhibits serotonin/noradrenaline reuptake; dental significance includes nausea, dizziness, and interaction with serotonergic drugs risking serotonin syndrome.

Question 2

Why is aspirin contraindicated as a post-operative analgesic for dental extractions?

Accepted Answer

Irreversibly inhibits platelet COX-1, preventing thromboxane A2 synthesis and impairing clotting for platelet lifespan (7–10 days)

Answer

Aspirin irreversibly acetylates platelet COX-1, eliminating thromboxane A2-mediated platelet aggregation for the platelet's entire lifespan, significantly increasing post-extraction bleeding risk.

Question 3

What is the reversal agent for opioid overdose and what is its mechanism?

Accepted Answer

Naloxone — competitive antagonist at mu, kappa, and delta opioid receptors

Answer

Naloxone is a competitive opioid receptor antagonist that reverses respiratory depression, sedation, and other opioid effects; its short duration may require repeated doses or infusion.

Question 4

What is prilocaine's main advantage over lidocaine for dental anaesthesia?

Accepted Answer

Lower systemic toxicity (lower CNS/cardiac toxicity), suitable for patients where adrenaline is contraindicated (used plain or with felypressin)

Answer

Prilocaine has lower systemic toxicity than lidocaine and can be used without adrenaline (or with felypressin) for patients with cardiovascular contraindications to adrenaline, providing a safer alternative.

Question 5

What is the pharmacological difference between COX-1 and COX-2 inhibition?

Accepted Answer

COX-1 inhibition causes GI side effects and antiplatelet effects; COX-2 inhibition is more selective for inflammatory pain with less GI toxicity

Answer

COX-1 is constitutive, protecting gastric mucosa (prostaglandins maintain mucus layer) and mediating platelet aggregation; COX-2 is inducible at sites of inflammation — selective COX-2 inhibitors have fewer GI effects.

MJDF Part 1 Practice Test

MJDF Part 1 Practice Test

MJDF Pharmacology & Pain Control 3